Aurobindo Pharma Limited

Výroční Annual Report FY2026 FY2026BSEPDF 3. srp 2026 před 3 měs. Výroční Submission of the Financial Results for the year ended March 31, 2026 FY2026BSEPDF 21. kvě 2026 před 5 měs. Kvartální Submission of unaudited financial results for the quarter and nine months period ended December 31, 2025. FY2026 · Q3BSEPDF 9. úno 2026 před 9 měs. Výroční Annual Report FY2025 FY2025BSEPDF 14. srp 2025 před 1 r. Kvartální submission of Unaudited financial results for the quarter and nine months period ended December 31, 2024 FY2025 · Q3BSEPDF 6. úno 2025 před 2 r. Kvartální Submitting the Unaudited Financial Results for the quarter and half year ended September 30, 2024 FY2025 · Q2BSEPDF 9. lis 2024 před 2 r. Kvartální Submission of Unaudited Financial Results for the 1st Quarter of FY 2024-25 FY2025 · Q1BSEPDF 10. srp 2024 před 2 r. Výroční Annual Report FY2024 FY2024BSEPDF 5. srp 2024 před 2 r. Výroční Submission of Audited Financial Results for the fourth quarter and financial year ended on March 31, 2024 FY2024BSEPDF 25. kvě 2024 před 2 r. Kvartální Submission of Financial Results for the quarter and nine months period ended 31st December 2023 FY2024 · Q3BSEPDF 10. úno 2024 před 3 r. Kvartální Unaudited Financial Results for the quarter ended 30th September 2023. FY2024 · Q2BSEPDF 9. lis 2023 před 3 r. Kvartální Un-audited financial results for the quarter ended June 30, 2023. FY2024 · Q1BSEPDF 12. srp 2023 před 3 r. Výroční Annual Report FY2023 FY2023BSEPDF 1. srp 2023 před 3 r. Výroční The Board of Directors of the Company at its meeting held today, May 27, 2023, has inter alia, considered and approved the standalone and consolidated Audited Financial Results of the .... FY2023BSEPDF 27. kvě 2023 před 3 r. Kvartální The Board of Directors of the Company at its meeting held today, February 9, 2023, has inter alia, transacted the following items of business: 1. Approved the standalone and consolidated .... FY2023 · Q3BSEPDF 9. úno 2023 před 4 r. Kvartální Pursuant to Regulation 23(9) of the Securities Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are submitting herewith disclosure on Related .... FY2023 · Q2BSEPDF 25. lis 2022 před 4 r. Kvartální The Board of Directors of the Company at its meeting held today, August 11, 2022, has, inter alia, considered and approved the Un-audited Financial Results of the Company for the First .... FY2023 · Q1BSEPDF 11. srp 2022 před 4 r. Výroční Annual Report FY2022 FY2022BSEPDF 9. čvc 2022 před 4 r. Výroční The Board of Directors of the Company at its meeting held today, May 30, 2022, has inter alia, approved the standalone and consolidated Audited Financial Results of the Company for the .... FY2022BSEPDF 30. kvě 2022 před 4 r. Kvartální The Board of Directors of the Company at its meeting held today, February 9, 2022, has, inter alia, considered and approved:- 1. the Un-audited Financial Results of the Company .... FY2022 · Q3BSEPDF 9. úno 2022 před 5 r. Kvartální The Board of Directors of the Company at its meeting held today, November 8, 2021, has, inter alia, considered and approved the Un-audited Financial Results of the Company for the Second .... FY2022 · Q2BSEPDF 8. lis 2021 před 5 r. Výroční Annual Report FY2021 FY2021BSEPDF 24. srp 2021 před 5 r. Kvartální The Board of Directors of the Company at its meeting held today, August 12, 2021, has inter alia, considered and approved the Un-audited Financial Results of the Company for the First Quarter .... FY2022 · Q1BSEPDF 12. srp 2021 před 5 r. Výroční Further to our letter dated August 3, 2021 intimating the date of 34th Annual General Meeting (AGM) of the Members of the Company and pursuant to Regulation 34 of the SEBI (Listing Obligation .... BSEPDF 4. srp 2021 před 5 r. Výroční The Board of Directors of the Company at its meeting held today, May 31, 2021, has inter alia, considered and approved the standalone and consolidated Audited Financial Results of the Company .... FY2021BSEPDF 31. kvě 2021 před 5 r. Kvartální The Board of Directors of the Company at its meeting held today, February 10, 2021, has, inter alia, considered and approved:- 1. the Un-audited Financial Results of the Company .... FY2021 · Q3BSEPDF 10. úno 2021 před 6 r. Kvartální Unaudited Financial Results for the quarter and half year ended 30th September 2020 FY2021 · Q2BSEPDF 11. lis 2020 před 6 r. Kvartální The Board of Directors of the Company at its meeting held today, August 12, 2020, has, inter alia, transacted the following businesses: 1. Approved the Un-audited Financial Results .... FY2021 · Q1BSEPDF 12. srp 2020 před 6 r. Výroční Annual Report FY2020 FY2020BSEPDF 4. srp 2020 před 6 r. Výroční The Board of Directors of the Company at its meeting held today, June 3, 2020, has inter alia, approved the standalone and consolidated Audited Financial Results of the Company for the .... FY2020BSEPDF 3. čvn 2020 před 6 r. Kvartální The Board of Directors of the Company at its meeting held today, February 6, 2020, has inter alia, transacted the following businesses: 1. Approved the Un-audited Financial Results .... FY2020 · Q3BSEPDF 6. úno 2020 před 7 r. Kvartální The Board of Directors of the Company at its meeting held today, November 12, 2019, has inter alia, transacted the following businesses: 1. Approved the Un-audited Financial Results .... FY2020 · Q2BSEPDF 12. lis 2019 před 7 r. Kvartální The Board of Directors of the Company at its meeting held today, August 7, 2019, has inter alia, approved the Un-audited Financial Results of the Company for the first Quarter ended June .... FY2020 · Q1BSEPDF 7. srp 2019 před 7 r. Výroční Annual Report FY2019 FY2019BSEPDF 5. srp 2019 před 7 r. Výroční The Board of Directors of the Company at its meeting held today, May 28, 2019 has approved the standalone and consolidated Audited Financial Results of the Company for the fourth Quarter .... FY2019BSEPDF 28. kvě 2019 před 7 r. Kvartální Approved the Un-audited Financial Results of the Company for the third Quarter and nine months period ended December 31, 2018 pursuant to Regulation 33 of SEBI (Listing Obligations and .... FY2019 · Q3BSEPDF 7. úno 2019 před 8 r. Kvartální The Board approved the Un-audited Financial Results of the Company for the second Quarter and half year ended 30th September, 2018 pursuant to Regulation 33 of SEBI (Listing Obligations .... FY2019 · Q2BSEPDF 12. lis 2018 před 8 r. Kvartální Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Un-audited Financial Results of the Company for the first .... FY2019 · Q1BSEPDF 9. srp 2018 před 8 r. Výroční The Board of Directors of the Company at its meeting held on 28th May, 2018 has inter-alia considered and approved the Audited Financial Results of the Company for the Quarter and Year .... FY2018BSEPDF 28. kvě 2018 před 8 r. Kvartální Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Un-audited Financial Results of the Company for the third .... FY2018 · Q3BSEPDF 7. úno 2018 před 9 r. Kvartální Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Un-audited Financial Results of the Company for the second .... FY2018 · Q2BSEPDF 9. lis 2017 před 9 r. Kvartální Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Un-audited Financial Results of the Company for the First .... FY2018 · Q1BSEPDF 9. srp 2017 před 9 r. Výroční The Board of Directors of the Company at its meeting held on 29th May 2017 has inter-alia considered and approved the Audited Financial Results of the Company for the year ended 31st March .... FY2017BSEPDF 29. kvě 2017 před 9 r. Kvartální Aurobindo Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended December 31, 2016 FY2017 · Q3BSEPDF 9. úno 2017 před 10 r. Kvartální Aurobindo Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended September 30, 2016 FY2017 · Q2BSEPDF 14. lis 2016 před 10 r. Kvartální Aurobindo Pharma Ltd has informed BSE about : 1. Result Press Release for the period ended June 30, 2016 FY2017 · Q1BSEPDF 23. srp 2016 před 10 r. Výroční Aurobindo Pharma Ltd has informed BSE about : 1. Result Presentation for the period ended March 31, 2016 FY2016BSEPDF 30. kvě 2016 před 10 r. Kvartální Aurobindo Pharma Ltd has informed BSE about : 1. Result Presentation for the period ended December 31, 2015 FY2016 · Q3BSEPDF 10. úno 2016 před 11 r. Kvartální Aurobindo Pharma Ltd has announced the following Unaudited results for the quarter ended September 30, 2015: The Unaudited Standalone results for the Quarter ended September 30, 2015 .... FY2016 · Q2BSEPDF 6. lis 2015 před 11 r. Kvartální Aurobindo Pharma Ltd has announced the following Unaudited results for the quarter ended June 30, 2015: The Unaudited Standalone results for the Quarter ended June 30, 2015 The .... FY2016 · Q1BSEPDF 12. srp 2015 před 11 r. Výroční Aurobindo Pharma Ltd has announced the following results for the quarter & year ended March 31, 2015: The Audited results for the Quarter ended March 31, 2015 The Company .... FY2015BSEPDF 28. kvě 2015 před 11 r. Kvartální Aurobindo Pharma Ltd has announced the following results for the quarter ended December 31, 2014: The Unaudited results for the Quarter ended December 31, 2014 The Company .... FY2015 · Q3BSEPDF 4. úno 2015 před 12 r.